Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

01.12.2014 | main topic

Renal denervation in the treatment of resistant arterial hypertension

verfasst von: Dr. Thomas Lambert, MD, Dr. Wilhelm Schützenberger, Clemens Steinwender

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 23-24/2014

Einloggen, um Zugang zu erhalten

Summary

Patients with resistant arterial hypertension have an increased risk of stroke, myocardial infarction, heart failure, and chronic kidney disease. In many cases, limitations of pharmacological treatment like intolerance and adherence to the antihypertensive medications are present in the clinical setting. In this context, new treatment options like trans-femoral sympathetic renal nerve denervation is, even after publication of the Symplicity HTN-3 trial, a promising new treatment option.
Vorheriger Artikel Electrical carotid baroreceptor stimulation
Nächster Artikel Pressurized intraperitoneal chemotherapy (PIPAC) in women with gynecologic malignancies: a review
Literatur
1.
Rodgers A, Ezzati M, Vander Hoorn S, et al.: Distribution of major health risks: findings from the Global Burden of Disease study. PLoS Med. 2004 Oct;1(1):e27. Epub 2004 Oct 19.
2.
The Task Force for the Management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013;31:1281–357.CrossRef
3.
4.
Chobanian AV, Bakris GL, Black HR, et al. Seventh report of Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42:1206–52.PubMedCrossRef
5.
Persell SD. Prevalence of resistant hypertension in the United States 2003–2008. Hypertension. 2011;57:1076–80.PubMedCrossRef
6.
Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125:1635–42.PubMedCentralPubMedCrossRef
7.
Marcum ZA, Amuan ME, Hanlon JT, et al. Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. J Am Geriatr Soc. 2012;60(1):34–41.PubMedCentralPubMedCrossRef
8.
Mazzaglia G, Ambrosioni E, Alaqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598–605.PubMedCrossRef
9.
De Geest S, Ruppar T, Berben L, et al. Medication non-adherence as a critical factor in the management of presumed resistant hypertension: a narrative review. Eurointervention. 2014;9:1102–9.PubMed
10.
Smith PA, Graham LN, Mackintosh AF, Stoker JB, Mary DA. Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens. 2004;17:217–22.PubMedCrossRef
11.
Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012;33:1058–66.PubMedCrossRef
12.
Schlaich M, Sobotka P, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54:1195–201.PubMedCrossRef
13.
DiBona GF, Esler M. Translational medicine. The antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298:R245–53.PubMedCrossRef
14.
Grassi G, Quarti-Trevano F, Seravalle G, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011;57:846–51.PubMedCrossRef
15.
Burns J, Sivananthan MU, Ball SG, et al. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation. 2007;115:1999–2005.PubMedCentralPubMedCrossRef
16.
Schlaich M, Sobotka P, Krum H, et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54:1195–201.PubMedCrossRef
17.
Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.PubMedCrossRef
18.
Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet. 1953;1:403–8.PubMedCrossRef
19.
Krum H, Schlaich M, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):602–9.CrossRef
20.
Esler M, Krum H, Sobotka P, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial. Lancet. 2010;376:1903–1909.PubMedCrossRef
21.
Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940–1946.
22.
Witkowski A, Prejbisz, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559–65.PubMedCrossRef
23.
Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Col Cardiol. 2012;59:901–9.CrossRef
24.
Mahfoud F, Vonend O, Kintscher U, et al. Kriterien der Deutschen Gesellschaft für Kardiologie, Deutschen Hochdruckliga e.V. DHL/Deutschen Gesellschaft für Hypertonie und Prävention und der Deutschen Gesellschaft für Nephrologiezur Zertifizierung von „Renale Denervations-Zentren (RDZ)“. Der Kardiologe. 2013;7:429–34.CrossRef
25.
Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;307(15):1393–401.CrossRef
26.
Gulati V, White WB. Review of the state of renal nerve ablation for patients with severe and resistant hypertension. J Am Soc Hypertens. 2013;7(6):484–93.PubMedCrossRef
27.
Eleid MF, Schwartz GL, Gulati R. Renal denervation for hypertension. Curr Probl Cardiol. 2014;39:35–51.PubMedCrossRef
28.
Bertrog SC, Sobotka PA, Sievert H. Renal denervation for hypertension. J Am Coll Cardiol Intv. 2012;5:249–58.CrossRef
29.
Worthley S. Safety and efficacy of a novel quadrapolar renal denervation catheter in patients with resistant hypertension: a first in man multicenter study. Abstract presented at the 2012 Annual Scientific Sessions of the European Association for Percutaneous Cardiovascular Interventions. Pairs, France; May 16, 2012.
30.
31.
Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60:419–24.PubMedCrossRef
32.
33.
Bhamra-Arizy P, Rao S, Muller DW. Renal artery stenosis following renal percutaneous denervation. Catheter Cardiovasc Interv. 2014; May 14. doi:10.1002/ccd.25546 (Epub ahead of print).
34.
Lambert T, Blessberger H, Grund M, et al. Late renal artery stenosis after percutaneous renal denervation. J Cardiovasc Med; 2014 (Epub ahead of print).
35.
Ukena C, Cremers B, Ewen S, et al. Response and non-response to renal denervation: who is the ideal candidate? Eurointervention. 2013;9:R54–7.PubMedCrossRef
36.
Lambert T, Blessberger H, Gammer V, et al. Effects of renal denervation on ambulatory blood pressure measurements in patients with resistant hypertension. Clin Cardiol. 2014;37(5):307–11.PubMedCrossRef
37.
Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128:132–40.PubMedCrossRef
38.
The Task Force for the Management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013;31:1281–357.CrossRef
39.
Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407–15.PubMedCrossRef
40.
Redon J, Campos C, Narciso ML, et al. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension. 1998;31:712–8.PubMedCrossRef
41.
Kario K, Lowy A, Munk VC, et al. 24-hour blood pressure control—a predictor for clinical outcomes. Curr Hypertens Rev. 2009;5:102–22.CrossRef
42.
Mancia G, Facchetti R, Bombelli M, et al. Long-term risk of mortality associated with selective and combined elevation in office, home and ambulatory blood pressure. Hypertension. 2006;47:846–53.PubMedCrossRef
43.
Mancia G, Parati G. Ambulatory blood pressure monitoring and organ damage. Hypertension. 2000;36:894–900.PubMedCrossRef
44.
Ohkubo T, Hozawa A, Nagai K, et al. Prediction of stroke by ambulatory blood pressure monitoring versus screening blood pressure measurements in a general population: the Ohasama study. J Hypertens. 2000;18:847–54.PubMedCrossRef
45.
Weber T, Zweiker R, Koppelstätter C, et al. Renale Sympathikusdenervierung 2014 in Österreich: Update der Empfehlungen der Österreichischen Gesellschaft für Hypertensiologie. Austrian J Hypertens. 2014;18(2):54–60.
Metadaten
Titel
Renal denervation in the treatment of resistant arterial hypertension
verfasst von
Dr. Thomas Lambert, MD
Dr. Wilhelm Schützenberger
Clemens Steinwender
Publikationsdatum
01.12.2014
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 23-24/2014
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-014-0330-9

Weitere Artikel der Ausgabe 23-24/2014

Stellungnahme zu Schwarz E., Maier M. – Publication output in the field of Public Health and its appreciation at political level in Austria, Wien Med Wochenschr (2014) 164:123–130

  • leserbrief

Relapsing advanced metatypical basal cell carcinomas (MTBCC) of the face: Surgical modalities

  • case report

Electrical carotid baroreceptor stimulation

  • main topic

Professor Gerhart Hitzenberger zum 85. Geburtstag

  • laudatio

Carotid interventions and blood pressure

  • main topic

Pressurized intraperitoneal chemotherapy (PIPAC) in women with gynecologic malignancies: a review

  • review